Evofem Biosciences, Inc. (EVFM) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Product sales, net	2.5	5.8	0.2	6.4	6.0	4.3	3.6	1.7
Product sales, net growth	-59.3%	36.7%	-94.9%	272.1%	224.9%	284.7%	2025.0%	515.8%
Operating Expenses:
Cost of goods sold	2.3	1.4	0.4	1.7	1.3	1.1	1.8	1.0
Research and development	0.4	0.5	1.7	5.2	7.7	10.4	8.7	8.7
Selling and marketing	2.2	3.9	7.0	11.9	12.3	12.7	24.9	30.5
General and administrative	4.9	3.6	3.2	6.3	9.1	9.0	5.7	5.0
Total operating expenses	9.8	9.4	12.2	25.1	30.5	33.2	41.0	45.1
Loss from operations	-7.3	-3.6	-12.1	-18.7	-24.4	-28.9	-37.4	-43.4
Operating margin	-298.5%	-61.6%	-6658.6%	-293.9%	-404.7%	-680.5%	-1048.1%	-2533.2%

Other income (expense):
Interest income	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
Other expense, net	-1.1	-0.3	-0.8	-0.4	-0.4	-0.5	-1.2	-1.2
Loss on issuance of financial instruments	0.0	-0.1	145.0		-71.2	-0.9
Change in fair value of financial instruments	-0.1	1.6	5.5	108.6	-30.0	-1.6	-12.9	-29.5
Total other income (expense), net	-1.2	1.2	3.7	108.2	-101.5	-3.0	-14.1	-30.7
Loss before income tax	-8.6	-2.4	-8.3	89.5	-126.0	-31.9	-51.5	-74.1
Income tax expense	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net loss	-8.6	-2.4	-8.3	89.5	-126.0	-31.9	-51.6	-74.1
Convertible preferred stock deemed dividends					1.9	-0.1
Net loss attributable to common stockholders	-8.6	-2.4	-11.5	89.5	-124.1	-32.0	-52.6	-74.1

Net loss per share, basic	($5.43)	($1.85)	$0.31	$1.09	($580.48)	($360.25)	($4.54)	($7.20)
Net loss per share, diluted	($5.43)	($1.85)	$0.31	($0.04)	($580.48)	($360.25)	($4.54)	($7.20)

Weighted-average shares used to compute net loss, basic	1.6	1.3	58.2	82.4	0.2	0.1	8.7	10.3
Weighted-average shares used to compute net loss, diluted	1.6	1.3	58.2	555.2	0.2	0.1	8.7	10.3